By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    physical health
    5 Ways Playing Games Can Improve Neural and Physical Health
    September 9, 2022
    Reasons For Hair Loss and Its Treatment
    Reasons For Hair Loss and Its Treatment
    February 16, 2022
    healthcare organization
    5 Actionable Strategies For Healthcare Organizations
    August 15, 2022
    Latest News
    7 Most Common Healthcare Accreditation Programs: Which Should You Use?
    August 20, 2025
    Hospital Pest Control and the Fight Against Superbugs
    August 20, 2025
    Hygiene Beyond The Clinic: Attention To Overlooked Non-Clinical Spaces
    August 13, 2025
    5 Steps to a Promising Career as a Healthcare Administrator
    August 3, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    4 Reasons Chris Cornell’s Death Raises Medical Ethics Questions
    December 19, 2018
    What If You Could Sell Your Vote?
    August 24, 2017
    The Sleepy American
    September 12, 2017
    Latest News
    How Social Security Disability Shapes Access to Care and Everyday Health
    August 22, 2025
    How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
    August 22, 2025
    How One Fall Can Lead to a Long Road of Medical Complications
    August 22, 2025
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Is Genetic Therapy the Future for Treating Leukemia and Other Blood Disorders?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Is Genetic Therapy the Future for Treating Leukemia and Other Blood Disorders?
Medical InnovationsSpecialtiesTechnology

Is Genetic Therapy the Future for Treating Leukemia and Other Blood Disorders?

Susan Scutti
Susan Scutti
Share
7 Min Read
genetic therapy for leukemia
SHARE

genetic therapy for leukemiaBlood disorders, including cancers like leukemia, often begin in the bone marrow where blood cells are produced, and from there the blood’s ability to properly perform some of its functions, such as fighting off infections, is thwarted.

genetic therapy for leukemiaBlood disorders, including cancers like leukemia, often begin in the bone marrow where blood cells are produced, and from there the blood’s ability to properly perform some of its functions, such as fighting off infections, is thwarted. Now, at the American Society of Hematology (ASH) annual meeting this past weekend, scientists have begun to offer evidence that experimental genetic therapies — precision medicines — may be effective and safe for treating blood disorder patients who fail to respond to standard treatments.

“It’s exciting to see these encouraging initial results with engineered immune cells, particularly such a durable response among patients who have very aggressive disease that has relapsed after standard treatments,” Dr. Laurence Cooper, of The University of Texas MD Anderson Cancer Center in Houston, stated in a press release. “With the right technology and laboratory expertise, the process of cell engineering is feasible for many patients.”

Precision Medicine

Precision medicine, also referred to as personalized medicine, is all about creating treatments tailored to an individual patient. This can be accomplished by first establishing a patient’s genetic profile and medical history, then examining those against existing clinical data to find appropriate disease targets, and finally engineering a cell therapy that can properly attack the origin of disease. Complicated? Wildly so, but this complex process represents the many and combined advancements in human genome studies, chemistry, technology, data-mining techniques, medicine — in short, all of science until now.

In particular, genetic therapies use DNA itself as a pharmaceutical agent. DNA is made up of nucleic acids, which are large biological molecules that may be catalyzed or activated by proteins. Commonly, genetic therapy will attempt to replace mutated genes with therapeutic genes introduced via a vector, which is able to penetrate a target cell and insert the genetic material into it. Once inside, the newly introduced DNA becomes expressed by the cell machinery, which in turn produces therapeutic proteins that target the disease — in short, a patient’s own re-engineered cells become soldiers in the war. Newer drugs that more precisely target pathways and proteins known to trigger CLL development, and leave normal cells unharmed, are proving to be more effective in promoting cancer cell death while safer for the patient.

In terms of blood disorders, stem cells contained within the bone marrow develop into three types of blood cells: red blood cells, white blood cells, or platelets. In blood cancers, the development process is interrupted by uncontrolled growth of an abnormal type of blood cell. In particular, chronic lymphocytic leukemia (CLL) occurs when abnormal white blood cells called lymphocytes accumulate in the blood, bone marrow, and lymph nodes, or other organs, causing these organs to enlarge. Although many patients with newly diagnosed blood disorders respond well to standard treatment, more than half of patients do not benefit from such therapies or experience a relapse after completing treatmentSeveral new, targeted therapies show promise to expand treatment options for CLL patients, as presented at the ASH conference.

Presentation of Studies

In cell therapy trials conducted at the Children’s Hospital of Philadelphia and the University of Pennsylvania, researchers used the chimeric antigen receptor (CAR) approach to manipulate the T cells — a type of lymphocyte — of 22 children and five adults with relapsed, treatment-resistant acute lymphocytic leukemia. After treatment with their own cells that had been re-engineered to seek, attack, and kill leukemic cells, 24 patients (19 children, five adults) achieved a complete response. One patient has remained in remission for a year and showed detectable engineered cells at 18 months post-infusion; unfortunately, six patients (five children, one adult) have since relapsed.

Another study concentrated on an experimental small molecule inhibitor designed to block the activity of a certain enzymes known as PI3K responsible for CLL cell signaling. Researchers enrolled 193 patients (average age 67), including 52 CLL patients with treatment–resistant or relapsed disease and 15 untreated CLL patients, in a Phase I trial testing dosage strengths from 8mg to 75mg. Researchers administered the new compound twice a day in 28–day cycles and observed clinical activity in relapsed or treatment–resistant patients at all doses studied. The experimental drug demonstrated activity in approximately half of the patients with a mutated form of a tumor suppressor gene (p53) that makes their cancer particularly hard to treat.

In one other trial conducted by the National Cancer Institute, 15 adult patients were treated with CAR-expressing T cells that targeted CD19, a protein on the surface of B cells (one type of white blood cell). All of the patients had advanced B cell malignancies, and eight had large B cell lymphomas. Working with a Los Angeles biotech firm, Kite Pharma Inc., the investigators infused all 15 patients with their own genetically-modified T cells following a chemotherapy conditioning regimen of cyclophosphamide and fludarabine. “They’ve had every treatment known to man,” study author Dr. James Kochenderfer of the National Cancer Institute, told CBS News.  Nevertheless, the results of the trial were extremely encouraging; six patients achieved complete remission and six achieved partial remission.

“Our data provide the first true glimpse of the potential of this approach in patients with aggressive lymphomas that, until this point, were virtually untreatable,” Kochenderfer stated in a press release. “This approach is still an early-stage experimental therapy, and we will continue our research to further improve the protocol and evaluate its value in additional patients with treatment-resistant disease.” Abstracts of these and many other studies appear on the ASH website.

(shutterstock)

TAGGED:blood disordersleukemia
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025
engineer fitting prosthetic arm
How Social Security Disability Shapes Access to Care and Everyday Health
Health care
August 20, 2025
a woman explaining the document
How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
Public Health
August 20, 2025

You Might also Like

Specialties

Alternative Insomnia Treatment: CBD Oil For Insomnia Symptoms

November 20, 2019
bionic limbs
Medical InnovationsTechnology

From War to Bionic Legs to Immortality

October 2, 2013
Health careTechnology

How Can You Improve Employee Health With Safety Software?

April 27, 2020
Understanding the Connection Between Asbestos and Mesothelioma
Cancer

Understanding the Connection Between Asbestos and Mesothelioma

February 10, 2025
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?